MIRA INFORM REPORT

 

 

Report Date :

06.09.2014

 

IDENTIFICATION DETAILS

 

Name :

INDUS PHARMA (PRIVATE) LIMITED

 

 

Registered Office :

Plot No. 65, Sector 27, Korangi Industrial Area, Karachi,

 

 

Country :

Pakistan

 

 

Date of Incorporation :

1968

 

 

Com. Reg. No.:

0002748

 

 

Legal Form :

Private Limited Company

 

 

Line of Business :

Manufacture & marketing of chemicals & pharmaceutical products

 

 

No. of Employees

272

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No complaints

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – June 1, 2014

 

Country Name

Previous Rating

(31.03.2014)

Current Rating

(01.06.2014)

Pakistan

B2

B1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

 

PAKISTAN ECONOMIC OVERVIEW

 

Decades of internal political disputes and low levels of foreign investment have led to slow growth and underdevelopment in Pakistan. Agriculture accounts for more than one-fifth of output and two-fifths of employment. Textiles account for most of Pakistan's export earnings, and Pakistan's failure to expand a viable export base for other manufactures has left the country vulnerable to shifts in world demand. Official unemployment was 6.6% in 2013, but this fails to capture the true picture, because much of the economy is informal and underemployment remains high. Over the past few years, low growth and high inflation, led by a spurt in food prices, have increased the amount of poverty. As a result of political and economic instability, the Pakistani rupee has depreciated more than 40% since 2007. The government agreed to an International Monetary Fund Standby Arrangement in November 2008 in response to a balance of payments crisis. Although the economy has stabilized since the crisis, it has failed to recover. Foreign investment has not returned, due to investor concerns related to governance, energy, security, and a slow-down in the global economy. Remittances from overseas workers, averaging about $1 billion a month since March 2011, remain a bright spot for Pakistan. However, after a small current account surplus in fiscal year 2011 (July 2010/June 2011), Pakistan's current account turned to deficit in the following two years, spurred by higher prices for imported oil and lower prices for exported cotton. Pakistan remains stuck in a low-income, low-growth trap, with growth averaging about 3.5% per year from 2008 to 2013. Pakistan must address long standing issues related to government revenues and energy production in order to spur the amount of economic growth that will be necessary to employ its growing and rapidly urbanizing population, more than half of which is under 22. Other long term challenges include expanding investment in education and healthcare, adapting to the effects of climate change and natural disasters, and reducing dependence on foreign donors

 

Source : CIA

 

 

 

Company name

                                   

INDUS PHARMA (PRIVATE) LIMITED

 

 

Full Address       

 

Registered Address & Factory

Plot No. 65, Sector 27, Korangi Industrial Area, Karachi, Pakistan

                       

Tel #

92 (21) 35062457, 35062458, 35062459

Fax #

92 (21) 35060168

Email

indus-p@cyber.net.pk

 

 

Short Description Of Business

 

a.

Nature of Business        

Manufacture & Marketing of Chemicals & Pharmaceutical Products

b.

Year Established

1968

c.

Registration #

0002748

 

 

Branches

                       

In Lahore at present

 

 

Auditors

 

G.M. Chottani & Co.

(Chartered Accountants)

306, 3rd Floor, Wind Song Place, K.C.H.S., Block 7 & 8, Shahrah-e-Faisal, Karachi, Pakistan

 

 

Legal Status

 

Subject Company was established as a Private Limited Company in 1968

 

6.

Authorized Capital

Rs. 200,000,000/- divided into 2,000,000 shares of Rs. 100/- each

 

Issued & Paid up Capital

Rs. 190,000,000/- divided into 1,900,000 shares of Rs. 100/- each

 

 

Details of Directors

 

Names

Nationality

Address

Occupation

Designation

Mr. Saeed Ismail

 

 

 

Mr. Khalid Saeed

 

 

 

Mr. Zahid Saeed

 

 

 

Mr. Anwar Saeed

Pakistani

 

 

 

 

Pakistani

 

 

 

 

Pakistani

 

 

 

 

Pakistani

 

 

 

Plot No. 65, Sector 27, Korangi Industrial Area, Karachi

 

Plot No. 65, Sector 27, Korangi Industrial Area, Karachi

 

Plot No. 65, Sector 27, Korangi Industrial Area, Karachi

 

Plot No. 65, Sector 27, Korangi Industrial Area, Karachi

Business

 

 

 

 

Business

 

 

 

 

Business

 

 

 

 

Business

 

 

 

Chief Executive

 

 

 

 

Director

 

 

 

 

Director

 

 

 

 

Director

 

 

Shareholders                

 

Names

No. of Shares

Mr. Saeed Ismail

 

Mrs. Aqila Saeed

 

Mr. Khalid Saeed

 

Mr. Zahid Saeed

 

Mr. Anwar Saeed

380,000

 

380,000

 

380,000

 

380,000

 

380,000

 

 

Associates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

 

A.         Subsidiary

 

None                                             

 

B.         Associated Companies

 

(1) Dynatis Pakistan (Pvt) Limited, Pakistan.

 

 

Products / Brand Names

 

Manufacture & marketing of Pharmaceutical Products by its brand names of ALLERVIL, ANZOL, ATROSOL, B.C.PLEX, BROMALEX, CELETAB,

CIMETAMAT, DYCLO, EXLOR, EXPLAT, FENTYL, GENTICILLIN,

HEMOTON-S, HEMOVIT, INCOBAL, INDAZOLE, INDOFER, INJEX,

INSTIGMINE, INZEE, IRNAZIN, KETASOL, LOTUS, MAXEF, MAXPAN, METOCLON, MILAM, NASOGIN, OFLOX, PARABAC, PENTAZOGON, STARLEV, VERICEF, VITACOMPON, VITROBION, XED

 

 

Number of Employees

 

272      

 

 

Annual Production Volume

 

The capacity and production of the company’s plant is indeterminable as it is multi-product and involves varying processes of manufacturing.

 

 

Annual Sales Volume

 

Year

In Pak Rupees

2013

2,382,832,253/-

 

 

Trade Suppliers (Foreign)

 

VASUDHA PHARMA, INDIA.

MURLI KRISHNA (PVT) LIMITED, INDIA.

ZHUHAI UNITED LABORATORIES CO., LTD, CHINA.

 

 

Distributors

 

Mainly exist at major cities of Pakistan

 

 

Exporting Countries

 

Mainly to Afghanistan & African Countries

 

 

Bankers

           

(1) Bank Alfalah Limited, Pakistan.

(2) Standard Chartered Bank, Pakistan.

(3) Habib Bank Limited, Pakistan.

(4) Faysal Bank Limited, Pakistan.

(5) Soneri Bank Limited, Pakistan.

 

(Total Mortgage obtained PKR 521,205,000/-)

 

 

Future Outlook

 

Company will continue to initiate successful marketing programs for all range of pharma products and will do utmost efforts to achieve effective results. It will also look for new opportunities for reducing costs, while keeping its pace with the fast changing economic environment. All these efforts will strengthen the business which will ultimately benefit the employees and the shareholders of the Company.

 

 

Memberships

 

Pakistan Pharmaceutical Manufacturers Associations.(PPMA)

Karachi Chamber of Commerce & Industry.(KCCI)

 

 

Foreign Exchange Rates

 

Currency

 

Unit

Pakistani Rupee

US Dollar

1

           Rs. 101.25

UK Pound

1

           Rs. 168.00

Euro

1

           Rs. 133.00

 

 

Comments

 

Subject Company was established in 1968 and is engaged in manufacture & marketing of Pharmaceutical Products. Market reputation is satisfactory. Trade relations are reported as fair. Subject can be considered for normal business dealings at usual trade terms & conditions.

 

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.60.44

UK Pound

1

Rs.98.64

Euro

1

Rs.78.20

 

INFORMATION DETAILS

 

Analysis Done by :

SUM

 

 

Report Prepared by :

NIS

 

               

RATING EXPLANATIONS

 

RATING

STATUS

PROPOSED CREDIT LINE

 

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

 

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

 

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

 

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

 

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

 

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

Credit not recommended

 

--

NB

 

New Business

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.